phi-amendment.pdf
... and Accountability Act (“HIPAA”) gives you the right to ask for an amendment to your medical record if you feel ... Page 1 of 2 (08/19) Request to Amend Protected Health Information The Health Insurance Portability ...
form-patient-request-to-inspect-phi-aug-19.pdf
... provide you the right to inspect medical records, billing records or other records that we may use to make ... Page 1 of 1 (08/19) Patient Request to Inspect Protected Health Information Federal and state law ...
Types of Cardiac Devices | NYU Langone Health
NYU Langone specialists use pacemakers, cardioverter defibrillators, and heart monitors to diagnose and manage heart rhythm disorders.
Payment & Insurance Coverage for Weight Loss Surgery | NYU Langone Health
Learn about payment and insurance options for weight loss surgery at NYU Langone’s Weight Management Program and how we help get authorization.
right-to-request-an-amendment.pdf
... Health is committed to maintaining accurate, clear, and complete medical and billing records ... Page 1 of 4 Issuing Department: Internal Audit, Compliance, and Enterprise Risk Management ...
REBYOTA for the Prevention of Recurrence of Clostridioides Difficile Infection (CDI) in Adult Patients: An Observational Study
This is a prospective observational cohort study designed to collect data on patients who received REBYOTA for the prevention of rCDI in the routine care setting. As all data collected for this study are observational, the decision to prescribe REBYOTA is at the treating physician’s discretion and independent from the decision to enroll the patient in the study. Adult patients who receive a prescription for REBYOTA to prevent rCDI are eligible to enroll according to the inclusion and exclusion criteria described below. Patients must enroll in the study between prescription and administration. This allows time for patients to enroll while still conducting the baseline measurement of patient-reported outcomes (CDI-DaySyms™) prior to administration. REBYOTAFor each patient, the current or presenting rCDI episode will be defined as the CDI episode just prior to receiving REBYOTA. If a patient receives REBYOTA more than once, the first dose will be used to define the presenting rCDI and to assess REBYOTA effectiveness.Baseline period will be defined as the time period between the date REBYOTA is prescribed and the date REBYOTA is administered.Data will be collected from patients’ medical records after obtaining informed consent. Data about clinical history, CDI events (primary and recurrent: severity, treatment), CDI-related symptoms, treatments, medical procedures, AEs, and healthcare resource utilization (i.e., hospitalizations and re-admissions) will be collected through 6 months of follow-up from the date of REBYOTA administration.
accounting-of-disclosures-of-phi.pdf
... for any reason other than those listed below must record the Disclosure in the patient’s medical record ... for an included purpose, the Disclosure must be recorded in the patient’s medical record or in the Accounting ...
sensitive-phi.pdf
... in the medical record, except for the following: • only initial Disclosures to insurance institutions must ... Page 1 of 4 Issuing Department: Internal Audit, Compliance, and Enterprise Risk Management ...
NYU Langone Radiology at Trinity | NYU Langone Health
NYU Langone Radiology at Trinity offers X-ray services in a convenient lower Manhattan location.
NYU Langone Radiology—NYU Langone Orthopedics—Westchester | NYU Langone Health
NYU Langone Radiology—NYU Langone Orthopedics—Westchester provides X-ray services.